公开(公告)号：US20210308257A1

公开(公告)日：2021-10-07

申请号：US17351363

申请日：2021-06-18

申请人： Medigen Vaccine Biologics Corporation ,  Dynavax Technologies Corporation

发明人： Tsun-Yung KUO ,  Charles CHEN ,  Chung-Chin WU ,  Yi-Jiun LIN ,  Meei-Yun Lin ,  Yu-Chi WU ,  John Darren CAMPBELL ,  Robert S. JANSSEN ,  David NOVACK

IPC分类号： A61K39/215 ,  C07K14/165 ,  C07K14/245

摘要： The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.

公开(公告)号：US20230110516A1

公开(公告)日：2023-04-13

申请号：US17908222

申请日：2021-03-01

申请人： Dynavax Technologies Corporation ,  MEDIGEN VACCINE BIOLOGICS CORPORATION

发明人： John D. CAMPBELL ,  Robert S. JANSSEN ,  David NOVACK ,  Tsun-Yung KUO ,  Charles CHEN ,  Chung-Chin WU ,  Yi-Jiun LIN ,  Meei-Yun LIN ,  Yu-Chi WU

IPC分类号： C07K14/005 ,  A61P31/14 ,  A61K39/215

摘要： The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.